 | Up a level |
van der van der Beek, Annemarie B. and Koomen, Jeroen V. and Dekkers, Claire C. J. and Barbour, Sean J. and Boulton, David W. and Gansevoort, Ron T. and Greasley, Peter J. and Abdul Gafor, Abdul Halim and Laverman, Gozewijn D. and Li, Qiang and Lim, Soo Kun and Stevens, Jasper and Vervloet, Marc G. and Singh, Sunita and Cattran, Daniel C. and Reich, Heather N. and Cherney, David Z. I. and Heerspink, Hiddo J. L. (2021) Evaluation of the pharmacokinetics and exposure-response relationship of dapagliflozin in patients without diabetes and with chronic kidney disease. Clinical Pharmacokinetics, 60 (4). pp. 517-525. ISSN 0312-5963, DOI https://doi.org/10.1007/s40262-020-00956-1.
Cherney, David Z. and Dekkers, Claire C. J. and Barbour, Sean J. and Cattran, Daniel and Gafor, Abdul Halim Abdul and Greasley, Peter J. and Laverman, Gozewijn D. and Lim, Soo Kun and Di Tanna, Gian Luca and Reich, Heather N. and Vervloet, Marc G. and Wong, Muh Geot and Gansevoort, Ron T. and Heerspink, Hiddo J. L. and Investigators, DIAMOND (2020) Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non -diabetic patients with chronic kidney disease (DIAMOND): A randomised, double-blind, crossover trial. Lancet Diabetes & Endocrinology, 8 (7). pp. 582-593. ISSN 2213-8587,
